-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 20, the official website of the State Food and Drug Administration showed that Qilu Pharmaceutical's cefepime hydrochloride for injection passed the consistency evaluation and was the first in China.
Source: official website of the State Food and Drug Administration
Cefepime hydrochloride can inhibit bacterial cell wall synthesis.
Cefepime hydrochloride currently on the market in China only has one dosage form for injection.
Application status of consistency evaluation of cefepime hydrochloride for injection
Source: Meinenet MED2.
At present, 9 companies have submitted supplementary applications for the consistency evaluation of cefepime hydrochloride for injection.
Qilu Pharmaceutical has reviewed injections
Source: Meinenet MED2.
Among the 18 over-reviewed injections, Cefepime Hydrochloride, Palonosetron Hydrochloride Injection, Ondansetron Hydrochloride Injection, Irinotecan Hydrochloride Injection, Fasudil Hydrochloride Injection, Oxaliplatin Seven injections for injection and bivalerudin for injection have been reviewed for the first time.
A wealth of over-reviewed varieties allows Qilu Pharmaceutical to "make a big show" in the national centralized procurement.
Qilu Pharmaceutical's products for consistency evaluation of injections (including new classifications for production)
Note: With *, no company has reviewed
Source: Meinenet MED2.
According to data from Minai.
Source: Minei.
Note: The statistics are as of April 21.